Treating Adult Patients with Growth Hormone Deficiency: Diagnostic Tools and New Treatment Options for Optimal Health
CMEO Webcast
Premiere Date: Wednesday, May 18, 2022This activity offers CE credit for:
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date: Thursday, May 18, 2023
%>
Begin Activity Now
Faculty
![]() |
Kevin C.J. Yuen, MD, FRCP (UK), FACE (Moderator) Medical Director of Barrow Pituitary Center Barrow Neurological Institute Professor of Medicine University of Arizona College of Medicine and Creighton School of Medicine Phoenix, AZ |
![]() |
Mark E. Molitch, MD Professor Emeritus Division of Endocrinology, Metabolism and Molecular Medicine Northwestern University Feinberg School of Medicine Chicago, IL |
![]() |
Julie M. Silverstein, MD Medical Director Pituitary Center Associate Professor of Medicine and Neurological Surgery Division of Endocrinology, Metabolism and Lipid Research Washington University School of Medicine St. Louis, MO |
Statement of Need
The clinical management of adult growth hormone deficiency (GHD) comprises caring for patients who are transitioning from pediatric to adult services, as well as patients with adult-onset (AO) GHD. There are unique challenges and opportunities in both scenarios, including who and when to test, which diagnostic tests to use, consideration of current and emerging treatment strategies, and improving patient adherence to therapies. The “art of medicine” and shared decision-making play important roles in GHD – as both medical and psychological factors need to be addressed to optimize outcomes.
In this OnDemand CMEO symposium, three experts in GHD follow the patient journeys of a young adult transitioning from pediatric care and a 50-year-old patient with AO-GHD. Clinical application of guidelines, a review of key study results, and the role of long-acting growth hormone preparations will be discussed.
Learning Objectives
At the end of this CME/CE activity, participants should be able to:
%End>- Incorporate evidence-based diagnostic testing to achieve a prompt and accurate diagnosis in individuals with GHD.
- Outline the clinical challenges associated with the management of GHD.
- Evaluate the current and emerging treatment strategies for the management of GHD.
Financial Support
Supported by an educational grant from Novo Nordisk, Inc.
Target Audience
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in endocrinology.
Credit Information
Jointly Accredited Provider
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians (ACCME):
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses (ANCC):
This activity is designated for 1.5 contact hours.
Note to Nurse Practitioners:
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.
California Residents:
This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.
Pharmacists (ACPE):
Pharmacists (ACPE): This application-based activity is approved for 1.5 contact hours (0.15 CEUs) of continuing pharmacy credit (JA0007185-0000-22-082-H01-P).
PAs (AAPA):
PAs (AAPA)
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 05/19/2023. PAs should only claim credit commensurate with the extent of their participation.
ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning formats:
Enduring material
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Yuen reports the following financial relationships:
Advisory Board: Amryt Pharma; Ascendis Pharma Group; Corcept; Crinetics; Ipsen Pharma; Novo Nordisk; Rani Therapeutics; Recordati; and Strongbridge Biopharma
Research Support: Grants paid to Barrow Neurological Institute: Amryt Pharma; Ascendis Pharma Group; Corcept; and Novartis
Dr. Molitch reports the following financial relationships:
Advisory Board: Strongbridge Biopharma
Consultant: Amryt Pharma and Corcept
Dr. Silverstein reports the following financial relationships:
Advisory Board: Chiasma, Inc.; Recordati S.p.A.; and Strongbridge Biopharma plc
The following peer reviewer and CME Outfitters staff report no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
This document was last modified on:
MMV-124-052022-68